Diversity of the intracellular mechanisms underlying the anti-tumor properties of indirubins

International Congress Series

Volumn 1304, Issue , 2007, Pages 60-74

  Meijer, Laurent ^a   Shearer, Jessica ^a   Bettayeb, Karima ^a   Ferandin, Yoan ^a  

^a CNRS   (France)

Author keywords

Alzheimer's disease; Arylhydrocarbon receptor; Cancer; Indigo; Indirubin; Kinase; Stat3

Indexed keywords

EID: 36049006209     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2007.07.041     Document Type: Article

References (86)

1. Balfour-Paul J. Indigo (1998), British Museum Press, London (264 pp.)
2. Cardon D. Le monde des teintures naturelles (2003), Presses Belin, Paris (586 pp.)
3. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique, Roscoff (27 chapters), 297 pp.
4. von Baeyer A. Synthese des Isoatins und Indigblaus. Chem. Ber. 11 (1878) 1228-1229
5. von Baeyer A. Synthese des Indigblaus. Chem. Ber. 11 (1878) 1296-1297
6. Fairbanks V.F. Blue gods, blue oil, and blue people. Mayo Clin. Proc. 69 (1994) 889-892
7. Hurry J.B. The Woad Plant and its Dye (1930), Oxford University Press, Oxford (328 pp.)
8. Balfour-Paul J. Indigo - a unique dye with a colourful story. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 1-6 (chapter 1)
9. Ricketts III. Indirubin, the red shade of indigo. Life in Progress. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds) (2006), Station Biologique de Roscoff 7-22 (chapter 2)
10. Cooksey C.J. Tyrian purple: 6,6′-dibromoindigo and related compounds. Molecules 6 (2001) 736-769
11. Cooksey C.J. Marine indirubins. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 23-30 (chapter 3)
12. Meijer L. La pourpre de Méditerranée, une source inattendue d'inhibiteurs de GSK-3. Médecine/Sciences 20 (2004) 516-518
13. Westley C.B., Vine K.L., and Benkendorff K. A proposed functional role for indole derivatives in reproduction and defence of the Muricidae (Neogastropoda: Mollusca). In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 31-44 (chapter 4)
14. Koren Z.C. HPLC-PDA analysis of brominated indirubinoid, indigoid and isatinoid dyes. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 45-53 (chapter 5)
15. Haubrichs R. Natural history and iconography of purple shells. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 55-70 (chapter 6)
16. Friedländer P. Uber den Farbstoff des antiken Purpurs aus Murex brandaris. Angew. Chem. 22 (1909) 2492-2494
17. Arnold W.N. King George III's urine and indigo blue. Lancet 34 (1996) 1811-1813
18. Allegri G., et al. Production of indirubin and indigoids in humans. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 89-101 (chapter 9)
19. Gillam E.M.J., et al. Oxidation of indole by cytochrome P450 enzymes. Biochem. 39 (2000) 13817-13824
20. Guengerich P.F., and Wu Z.-L. Biosynthesis of novel indirubins by recombinant cytochrome P450 enzymes. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 79-87 (chapter 8)
21. MacNeil I.A., et al. Expression and isolation of antimicrobial small molecules from soil DNA libraries. J. Mol. Microbiol. Biotechnol. 3 (2001) 301-308
22. Lim H.K., et al. Characterization of a forest soil metagenome clone that confers indirubin and indigo production on Escherichia coli. Appl. Environ. Microbiol. 71 (2005) 7768-7777
23. Ensley B.D., et al. Expression of naphthalene oxidation genes in Escherichia coli results in the biosynthesis of indigo. Science 222 (1983) 167-169
24. Kim I.-C., Chang H.-C., and Oriel P. Production of indigo and indirubin by Escherichia coli containing a phenol hydroxylase gene of Bacillus stearothermophilus. J. Microbiol. Biotechnol. 7 (1997) 197-199
25. Rui L., Reardon K.F., and Wood T.K. Protein engineering of toluene ortho-monooxygenase of Burkholderia cepacia G4 for regiospecific hydroxylation of indole to form various indigoid compounds. Appl. Microbiol. Biotechnol. 66 (2005) 422-429
26. McClay K., Boss C., and Steffan R.J. Mutations of toluene-4-monooxygenase that alter regiospecificity of indole oxidation and lead to production of novel indigoid pigments. Appl. Environ. Microbiol. 71 (2005) 5476-5483
27. Meyer A., et al. Hydroxylation of indole by laboratory-evolved 2-hydroxybiphenyl 3-monoooxygenase. J. Biol. Chem. 277 (2005) 34161-34167
28. Tang W., and Eisenbrand G. Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine (1992), Springer-Verlag, Heidelberg
29. Han J. Traditional Chinese medicine and the search for new antineoplastic drugs. J. Ethnopharmacol. 24 (1988) 1-17
30. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 12 (1994) 53-63
31. Chinese Pharmacopoeia, Edition 1995, Vol. 1.
32. Institute of Haematology, Chinese Academy of Medical Sciences. Clinical studies of Dang Gui Lu Hui Wan in the treatment of CML. Chin. J. Intern. Med. 15 (1979) 86-88
33. Wu L.M., Yang Y.P., and Zhu Z.H. Studies on the active principles of Indigofera tinctoria in the treatment of CML. Comm. Chinese Herbal Med. 9 (1979) 6-8
34. Zheng Q.T., Lu D.J., and Yang S.L. Pharmacological studies of indirubin. I. Antitumor effect. Comm. Chinese Herbal Med. 10 (1979) 35-39
35. 3H-indirubin. Comm. Chinese Herbal Med. 10 (1979) 19-21
36. Zhang S.X. Studies on the chemical constituents of Isatis indigotica root. Chinese Trad. Herb Drugs 14 (1983) 247-248
37. Chen D.H., and Xie J.X. Chemical constituents of traditional Chinese medicine Qing Dai. Chinese Trad. Herbal Drugs 15 (1984) 6-8
38. Xiao Z., et al. Indirubin and Meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma 43 (2002) 1763-1768
39. Xiao Z., and Hao Y. From Danggui Luhui Wang to meisoindigo: experience in the treatment of chronic myelogenous leukemia in China. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 203-208 (chapter 20)
40. Easton C.J., Harper J.B., and Lincoln S.F. A molecular reactor for the synthesis of indirubin and related compounds. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 127-134 (chapter 13)
41. Merz K.-H., and Eisenbrand G. Chemistry and structure activity of indirubins. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 135-145 (chapter 14)
42. Magiatis P., and Skaltsounis A.L. From Hexaplex trunculus to new kinase inhibitory indirubins. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 147-156 (chapter 15)
43. Li C., et al. The synthesis, antileukemic activity, and crystal structures of indirubin derivatives. Bull. Chem. Soc. Jpn. 69 (1996) 1621-1627
44. Hoessel R., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1 (1999) 60-67
45. Leclerc S., et al. Indirubins inhibit glycogen synthase kinase- 3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease-a property common to most CDK inhibitors?. J. Biol. Chem. 276 (2001) 251-260
46. Jautelat R., et al. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. ChemBioChem 6 (2005) 531-540
47. Moon M.J., et al. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg. Med. Chem. 14 (2006) 237-246
48. Ferandin Y., et al. 3′-substituted, 7-halogenoindirubins, a new class of cell death inducing agents. J. Med. Chem. 49 (2006) 4638-4649
49. Meijer L., et al. GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 10 (2003) 1255-1266
50. Adachi J., et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 276 (2001) 31475-31478
51. Kosmopoulou M.N., et al. Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex. Eur. J. Biochem. 271 (2004) 2280-2290
52. Xie Y., et al. Indirubin-3′-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci. Lett. 367 (2004) 355-359
53. Nam S., et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5998-6003
54. Weinmann H., and Metternich R. Drug discovery process for kinase inhibitors. ChemBioChem 6 (2005) 455-459
55. Fischer P.M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem. 11 (2004) 1563-1583
56. Knockaert M., Greengard P., and Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23 (2002) 417-425
57. Meijer L., Flajolet M., and Greengard P. Pharmacological inhibitors of glycogen synthase kinase-3. Trends Pharmacol. Sci. 25 (2004) 471-480
58. Malumbres M., and Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30 (2005) 630-641
59. Mapelli M., et al. Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 48 (2005) 671-679
60. Noble M.E., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
61. Davies T.G., et al. Inhibitor binding to active and inactive CDK2. The crystal structure of a CDK2-cyclin A/indirubin-5-sulphonate. Structure 9 (2001) 389-397
62. Holton S., et al. Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. Structure 11 (2003) 1329-1337
63. Endicott J.A., and Noble M.E.M. Molecular recognition of indigoids. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 191-201 (chapter 19)
64. Jope R.S., and Johnson G.V.W. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
65. Polychronopoulos P., et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 47 (2004) 935-946
66. Bertrand J.A., et al. Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol. 33 (2003) 393-407
67. Bain J., et al. The specificities of protein kinase inhibitors: an update. Biochem. J. 371 (2003) 199-204
68. Ribas J., et al. 7-bromoindirubin-3′-oxime induces caspase-independent cell death. Oncogene 25 (2006) 6304-6318
69. Bach S., et al. Roscovitine targets: protein kinases and pyridoxal kinase. J. Biol. Chem. 280 (2005) 31208-31219
70. Marlowe J.L., and Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J. Cell. Biochem. 96 (2005) 1174-1184
71. Spink B.C., et al. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin. Biochem. Pharmacol. 66 (2003) 2313-2321
72. Adachi J., et al. Comparison of gene expression patterns between 2,3,7,8-tetrachlorodibenzo-p-dioxin and a natural arylhydrocarbon receptor ligand, indirubin. Toxicol. Sci. 80 (2004) 161-169
73. Guengerich F.P., et al. Aryl hydrocarbon receptor response to indigoids in vitro and in vivo. Arch. Biochem. Biophys. 423 (2004) 309-316
74. Knockaert M., et al. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the anti-proliferative effects of indirubins. Oncogene 23 (2004) 4400-4412
75. Sugihara K., et al. Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo. Biochem. Biophys. Res. Commun. 318 (2004) 571-578
76. Matsuda T., and Adachi J. Aryl hydrocarbon receptor ligand activity of indirubin. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 169-175 (chapter 17)
77. Denison M.S., et al. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 157-167 (chapter 16)
78. Oikonomakos N.G., et al. Indirubin and indigo analogues as potential inhibitors of glycogenolysis: structural basis of glycogen phosphorylase inhibition. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 177-189 (chapter 18)
79. De Landsheere B.C. Effect of indirubin on white blood cell count in the guinea pig. Experientia 7 (1951) 307-308
80. Damiens E., et al. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 20 (2001) 3786-3797
81. Marko D., et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumor cells. Br. J. Cancer 84 (2001) 283-289
82. Lee J.-W., et al. Induction of apoptosis by a novel indirubin-3′-monoxime, a CDK inhibitor, in human cancer cells. Bioorg. Med. Chem. Lett. 15 (2005) 3948-3952
83. Ribas J., Garrofe-Ochoa X., and Boix J. Characterization of the cell death processes triggered by indirubin-derivatives in neuroblastoma cells. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 215-226 (chapter 22)
84. Suzuki K., et al. Indirubin, a Chinese anti-leukemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells. Br. J. Haematol. 130 (2005) 681-690
85. Kortylewski M., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11 (2005) 1314-1321
86. Meijer L., et al. Diversity of intracellular mechanisms underlying the anti-tumor properties of indirubins. In: Meijer L., Guyard N., Skaltsounis L.A., and Eisenbrand G. (Eds). Indirubin, the Red Shade of Indigo. Life in Progress (2006), Station Biologique de Roscoff 235-246 (chapter 24)